DrugBiological
Homo sapiens whole clinical trials
- studies test it
- 31
- open now
- 4
- in phase 3
- 12
- first study started
- 2002
Keep track of what changes. Save the homo sapiens whole studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
27 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 3 |
| 2019 | 1 |
| 2021 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 14
- Phase 3
- 12
- Phase 4
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 10
CSL Behring (6) · Baxalta now part of Shire (3) · Grifols Therapeutics LLC (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Nabi Biopharmaceuticals (2) · Nycomed (2) · Oregon Health and Science University (1) · Axogen Corporation (1)
Often tested with
Tested in the same studies.
Prothrombin complex concentrate (2) · Immunoglobulins, Intravenous (1) · Hyaluronidase (human recombinant) (1) · Zidovudine (1)
Studies
Open first, then newest update. How each study uses homo sapiens whole is read from its arms, and is right about nine times in ten.
Testing it · 31
- Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive SurgeryRecruitingPhase 3CSL BehringNCT06617897Written as CSL511 Fibrinogen concentrate (human)
- IVIG for Infection Prevention After CAR-T-Cell TherapyRecruitingPhase 2Fred Hutchinson Cancer CenterNCT05952804Written as Immune Globulin Infusion (Human), 10% Solution
- Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)RecruitingPhase 4Camille N. Kotton, MDNCT06958796Written as Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
- Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for PreventionRecruitingPhase 2Rochester General HospitalNCT05764993Written as CUVITRU - Ig subcutaneous human 20%
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin DeficiencyCompletedPhase 1/2Grifols Therapeutics LLCNCT04722887Written as Liquid Alpha1-Proteinase Inhibitor (Human)
- Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac SurgeryTerminatedPhase 4SHI JiaNCT04244981Written as Prothrombin Complex Concentrate, Human
- Prehospital Kcentra for Hemorrhagic ShockActive, not recruitingPhase 2Oregon Health and Science UniversityNCT04019015Written as Prothrombin Complex Concentrate, Human
- Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve RepairCompletedPhase 3Axogen CorporationNCT01809002Written as Processed Nerve Allograft (human)
- Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)TerminatedPhase 2Grifols Therapeutics LLCNCT04547140Written as Liquid Alpha1-Proteinase Inhibitor (Human)
- Impact of Two Guided Transfusion Strategies on Blood Product Requirements in Liver Transplantation.Status unknownPhase 4Antoni Sabaté PesNCT04405518Written as Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]
- A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected ChildrenCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000827Written as Anti-HIV Immune Serum Globulin (Human)
- The Safety and Effectiveness of Human Monoclonal Antibody, F105, in the Treatment of HIVCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001105Written as F105 Monoclonal Antibody (Human)
- Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver TransplantationTerminatedPhase 2ADMA Biologics, Inc.NCT00473824Written as Hepatitis C Immune Globulin Intravenous (Human) 5%
- Phase 2/3 Study of IGSC, 20% in PIDDCompletedPhase 2/3Baxalta now part of ShireNCT01218438Written as Immune Globulin Subcutaneous (Human), 20% Solution
- Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaCompletedPhase 3ShireNCT02584959Written as C1 esterase inhibitor [human] liquid
- Tolerability and Safety of IGI, 10% With rHuPH20 in PIDDCompletedPhase 2/3Baxalta now part of ShireNCT01485796Written as Immune Globulin Infusion (Human), 10%
- Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C DeficiencyCompletedPhase 2/3Baxalta now part of ShireNCT00157118Written as Protein C Concentrate (Human) Vapor Heated
- Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.CompletedPhase 4CSL BehringNCT00670007Written as Alpha1- proteinase inhibitor [human]
- CSL Behring Sclero XIIIStatus unknownPhase 2University College, LondonNCT02551042Written as Fibrogammin®P, coagulation factor XIII concentrate (Human)
- Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular SurgeryCompletedPhase 3CSL BehringNCT01475669Written as Fibrinogen Concentrate (Human) (FCH)
See all 31 studies that test homo sapiens whole →
Given in every arm · 2 — homo sapiens whole is usual care beside what is tested
- Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage at Pre-hospital Phase of Care.CompletedPhase 1/2Banc de Sang i TeixitsNCT03780894Written as Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]
- Immune Globulin Subcutaenous (Human), 20%CompletedPhase 2/3Baxalta now part of ShireNCT01412385Written as Immune Globulin Subcutaneous (Human), 20%